QKI-V5 is downregulated in CNS inflammatory demyelinating diseases

Area of Science:

• Neuroimmunology
• Molecular Neuroscience

Background:

• Neuromyelitis optica (NMO) and multiple sclerosis (MS) are central nervous system (CNS) inflammatory demyelinating diseases.
• Previous research identified upregulated miRNAs in NMO patients, targeting the QKI gene, crucial for myelination.
• QKI variants, including QKI-V5, are generated via alternative splicing.

Purpose of the Study:

• To investigate the expression levels of QKI variants in patients with NMO and MS.
• To examine QKI variant expression in the blood and brain of a mouse model for CNS inflammatory demyelinating disease.

Main Methods:

• Quantified RNA and protein expression of QKI variants (QKI-V5, QKI-V6, QKI-V7) in blood samples from NMO and MS patients.
• Assessed the impact of patient sera on QKI expression in normal peripheral blood mononuclear cells (PBMCs) and glial cells.
• Correlated QKI expression changes in the blood and brain of the experimental autoimmune encephalomyelitis (EAE) mouse model.

Main Results:

• QKI-V5 RNA and protein expression were significantly decreased in the blood of NMO and MS patients.
• Patient sera markedly reduced QKI-V5 expression in normal PBMCs and glial cells.
• A corresponding decrease in QKI-V5 expression was observed in both the blood and brain of EAE mice.

Conclusions:

• Downregulation of QKI-V5 in CNS inflammatory demyelinating diseases is likely mediated by a circulating factor.
• Reduced QKI-V5 expression may impact remyelination by regulating myelin-associated genes.